AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02819661
Drug: Spinal anesthesia with intrathecal morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: is a form of regional anaesthesia involving injection of a local anaesthetic into the subarachnoid space
Trial: NCT01814618
Drug: Budesonide Respules
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months.
Trial: NCT03194685
Drug: FF-10101-01
RxNorm normalized name: FF-10101-01
DrugBank: FF-10101-01 (DB16050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF-10101-01 will be administered orally once a day on Days 1-28 of a 28-day cycle. In Phase 1, the dose escalation will proceed until MTD is reached.
Trial: NCT05102045
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine were given for Alzheimer's disease. .
Trial: NCT04115306
Drug: fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: SERDs
Trial: NCT02673996
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: incremental small doses of IV phenylephrine to find the dose that transiently raises systolic blood pressure by 25 mmHg
Trial: NCT02673996
Drug: Isoproterenol
RxNorm normalized name: Isoproterenol
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: incremental small doses of IV isoproterenol to find the dose that transiently raises heart rate by 25 bpm
Trial: NCT00076323
Drug: Primaquine
RxNorm normalized name: Primaquine
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00119132
Drug: artesunate-amodiaquine
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00119132
Drug: sulphadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03839888
Drug: 0.125% Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients used 0.125% atropine eyedrop per night before sleep for 7 days.
Trial: NCT01140178
Drug: HPPH
RxNorm normalized name: HPPH
DrugBank: 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (DB15243)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01331083
Drug: PX-866
RxNorm normalized name: PX-102
DrugBank: PX-102 (DB15416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PX-866: 8mg orally taken daily
Trial: NCT01637961
Drug: Alisertib
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03828773
Drug: Posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole is a triazole with broad-spectrum activity, to include Candida species, Aspergillus species, and other fungal pathogens, including the Zygomycetes. Posaconazole is available as slow release tablets (300mg/day) and as intravenous (IV) formulation (300mg/day) and is licensed and approved in Switzerland for the prevention of IFI, including mold and yeast infections, in patients \>18 years who are at high risk of developing these types of infection (patients with long-term neutropenia or HCT recipients). Furthermore, international guidelines recommend posaconazole for primary antifungal prophylaxis in high-risk patients, such as AML patients with prolonged neutropenia. Posaconazole is available in Switzerland under the name of Noxafil® in capsules of 100mg, suspension of 40mg/mL and intravenous formulation of 300mg/16.7 mL.
Trial: NCT03828773
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole is an antifungal with activity against most Candida species. Fluconazole is licensed and approved in Switzerland for prophylaxis of IC in patients with neutropenia induced by chemotherapy or radiotherapy at a daily dose of 200 to 400 mg once daily. Fluconazole (200 mg or 400 mg once daily) is still currently used as primary antifungal prophylaxis (standard of care) in all 7 centers participating in this trial. Fluconazole is available in Switzerland under the name of Diflucan® in capsules of 50 mg, 150 mg and 200 mg and in powder for preparation of suspension (50 mg/5 ml and 200 mg/5 ml (forte)) or perfusion (2 mg/1 ml). Several generics of Diflucan® are authorized in Switzerland. Prescribing Diflucan® or any of its generics will remain at the discretion of and based on the standard operating procedures (SOP) at each institution.
Trial: NCT04321733
Drug: Amoxicillin Clavulanate
RxNorm normalized name: amoxicillin / clavulanate
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous drug intake of our drug.
Trial: NCT04006847
Drug: Eicosapentaenoic Acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic Acid once per day orally
Trial: NCT02292433
Drug: PF-04937319 high dose
RxNorm normalized name: PF-04937319
DrugBank: PF-04937319 (DB15009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, 150 mg with breakfast plus 100 mg with lunch, 7 days
Trial: NCT02292433
Drug: PF-04937319 low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: PF-04937319 (DB15009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, 50 mg with breakfast plus 50 mg with lunch, 7 days
Trial: NCT01082445
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg, 1 tablet 3 times a day for 3 months
Trial: NCT04510220
Drug: Ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab (OMB157) is a fully human anti-CD20 monoclonal antibody (mAb) self-administered by a once-monthly subcutaneous injection that is in development for MS. Ofatumumab drug product (also referred as OMB157) is formulated as 20 mg/0.4 mL (50 mg/mL) solution for injection, provided in autoinjectors, for subcutaneous administration. The autoinjectors contain a small overfill to allow for a complete withdrawal of the labeled amount (20 mg) of ofatumumab.
Trial: NCT01425775
Drug: vitamin D 25(OH)D
RxNorm normalized name: Ac-D-Leu-OH
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000IU/day for 12 months
Trial: NCT00321724
Drug: cediranib maleate
RxNorm normalized name: maleate
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01915264
Drug: Acarbose/Metformin (Glucobay M, BAY81-9783)
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose (25/50mg) and Metformin (500mg) in fixed dose combination.
Trial: NCT00625742
Drug: Atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol will only be taken if there's evidence of increased sympathetic activity (resting heart rate \>110 beats/min) or resting energy expenditure (REE) \> 110% of predicted.
Trial: NCT01823510
Drug: Ticagrelor + Aspirin
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).
Trial: NCT01823510
Drug: Clopidogrel + Aspirin
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).
Trial: NCT01920555
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose of Ketamine will be 0.1 mg/kg - one single infusion
Trial: NCT01920555
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose of Ketamine will be 0.2 mg/kg - one single infusion
Trial: NCT01920555
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose of Ketamine will be 0.5 mg/kg - one single infusion
Trial: NCT01920555
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose of Ketamine will be 1.0 mg/kg - one single infusion
Trial: NCT01920555
Drug: Placebo Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose of Midazolam (active placebo) will be 0.045 mg/kg - one single infusion
Trial: NCT00234390
Drug: Pulmicort (budesonide) pMDI
RxNorm normalized name: Pulmicort
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00168402
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT04280848
Drug: UCPVax
RxNorm normalized name: UCPVax
DrugBank: UCPVax (DB17509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The UCPVax vaccination protocol will start at least one month after glioblastoma patients have completed the concomitant radiochemotherapy (Radiotherapy + Temozolomide RT/TMZ).~UCPVax vaccine will injected subcutaneously at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccination one month after the last injection and then every 8 weeks for 12 months maximum.
Trial: NCT04280848
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 additional monthly cures of Temozolomide (after concomitant radiotherapy and temozolomide) according to standard of care
Trial: NCT01081262
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01081262
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01081262
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT02595892
Drug: Berzosertib
RxNorm normalized name: Berzosertib
DrugBank: Berzosertib (DB11794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02595892
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02595892
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03731234
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance
Trial: NCT03671265
Drug: SHR-1210
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
Trial: NCT02128828
Drug: cenicriviroc
RxNorm normalized name: Cenicriviroc
DrugBank: Cenicriviroc (DB11758)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc
Trial: NCT04072952
Drug: ARV-471
RxNorm normalized name: Arv-110 (protac)
DrugBank: Bavdegalutamide (DB19032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parts A and B: ARV-471 administered QD or BID for 28 day cycles.
Trial: NCT04072952
Drug: ARV-471 in combination with palbociclib (IBRANCE®)
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days
Trial: NCT03671265
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2.
Trial: NCT04542499
Drug: Tavapadon
RxNorm normalized name: Tavapadon
DrugBank: Tavapadon (DB14899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive tavapadon 5 to 15 mg tablet QD orally for 27 weeks.
Trial: NCT03101293
Drug: TAK-831
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-831 film-coated tablet.
Trial: NCT00010933
Drug: chamomile tea
RxNorm normalized name: Chamomile Tea
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00850161
Drug: aspart
RxNorm normalized name: Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Meal-time insulin. Administered subcutaneously based on routine clinical therapy.
Trial: NCT01165333
Drug: Cilengitide dose escalation
RxNorm normalized name: peanut allergenic extract
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilengitide will be administered intravenously over 60 minutes, twice a week, at a given dose.~The Cilengitide dose (mg/m²/infusion)levels are as follows :~* 240~* 480~* 720~* 1200~* 1800
Trial: NCT02833857
Drug: Etelcalcetide
RxNorm normalized name: Etelcalcetide
DrugBank: Etelcalcetide (DB12865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single IV-bolus dose of 0.035 mg/kg etelcalcetide into the venous line of the dialysis circuit at the end of a hemodialysis session.
Trial: NCT00370669
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00370669
Drug: triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01165333
Drug: Cilengitide
RxNorm normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations
Trial: NCT01498419
Drug: Moxifloxacin (M)
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01498419
Drug: Pretomid (Pa)
RxNorm normalized name: pretomanid
DrugBank: Pretomanid (DB05154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01498419
Drug: Pyrazinamide (Z)
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01270841
Drug: Androxal
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule of either 12.5 mg or 25 mg Androxal, 1x daily for 3 months
Trial: NCT01326702
Drug: Bendamustine Hydrochloride
RxNorm normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01326702
Drug: Veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04551079
Drug: TAK-994
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-994 tablets.
Trial: NCT00163436
Drug: Ciclesonide
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01416649
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide is started for the treatment of type 2 diabetes as determined by the patients regular physician. The dose will be 5-10 micrograms twice daily which is the standard dose. The medication is given by self-administered subcutaneous injection. The medication may continue for the treatment of the type 2 diabetes after the study is completed after 3 months.
Trial: NCT04733235
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ultrasound measurements of endometrial thickness at the end of the estrogen phase and the day of embryo transfer.
Trial: NCT00086879
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00086879
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00086879
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04250116
Drug: NOAC monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients enrolled in the NOAC monotherapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 20 mg once daily for 2 years after randomization. Reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (15 mg once daily) will be used in patients meeting the pre-defined criteria for dose reduction. Warfarin is allowed to use at the physicians' discretion.
Trial: NCT04250116
Drug: Dual antithrombotic therapy with NOAC and clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients enrolled in the dual antithrombotic therapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 15 mg once daily and clopidogrel 75 mg daily for 2 years after randomization. Reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (10 mg once daily) will be used in patients meeting the pre-defined criteria for dose reduction. Warfarin is allowed to use at the physicians' discretion.
Trial: NCT02402933
Drug: Nasal Glucagon
RxNorm normalized name: glucagon Nasal Powder
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 mg nasal glucagon powder
Trial: NCT01869491
Drug: Compound Sodium Alginate Double Action Chewable Tablets
RxNorm normalized name: Sodium Alginate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 tablets four times daily
Trial: NCT02156739
Drug: Gadobutrol
RxNorm normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02156739
Drug: Gadoxetate Disodium
RxNorm normalized name: Gadoxetate Disodium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01110499
Drug: AGN-210961 Formulation 4
RxNorm normalized name: AGN-201904
DrugBank: AGN-201904 (DB13135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-210961 Formulation 4 in one eye once daily for 7 days.
Trial: NCT03958565
Drug: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
RxNorm normalized name: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given Q12 weeks for bone disease as standard of care
Trial: NCT01110499
Drug: bimatoprost ophthalmic solution 0.03%
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: bimatoprost ophthalmic solution 0.03% (LUMIGAN®) in both eyes once daily for 4 weeks.
Trial: NCT01337687
Drug: Intranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.
Trial: NCT01224756
Drug: Tinoridine HCl
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Tinoridine (DB13001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinoridine HCl 50 mg, orally, 2 capsules three times daily for up to 4 days.
Trial: NCT03405337
Drug: Conventional FVIII replacement therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advate, Kogenate FS, Helixate, Novoeight, Nuwiq, Recombinate, Xyntha
Trial: NCT02193698
Drug: Lenalidomide+Dexamethasone
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
Trial: NCT01440478
Drug: LY2140023
RxNorm normalized name: LY2140023
DrugBank: LY2140023 (DB05096)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01440478
Drug: Ammonium chloride
RxNorm normalized name: Ammonium Chloride
DrugBank: Ammonium chloride (DB06767)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01440478
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00852956
Drug: Betahistine
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:~Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated)~On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio:~Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00
Trial: NCT02803762
Drug: Pacritinib
RxNorm normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg \[14C\]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose following at least a 10-hour fast (not including water) on Day 1